Globus Medical updates guidance after NuVasive merger close, shares react on NASDAQ

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 18:39.

Globus Medical Inc (US3795772082) has sharpened its post-merger guidance following the closing of its all-stock acquisition of NuVasive and the first quarters of combined reporting. The spine specialist, whose Class A shares trade on NASDAQ, now details revenue expectations, integration costs and margin targets that analysts follow closely, according to the company's recent filings and presentations. Globus Medical investor relations material

What the latest guidance shows

In its recent investor communication around the NuVasive transaction, Globus Medical Inc described expected cost and revenue synergies from the combined spine and orthopedics portfolio, with management affirming that the deal should be accretive to adjusted earnings over the medium term, according to company statements. SEC filings outlining the NuVasive merger

The company has indicated in its merger materials that annualized cost synergies are expected to be realized through streamlining overlapping functions, optimizing manufacturing footprints and integrating commercial organizations, while also targeting cross-selling opportunities in the expanded surgeon customer base, as described in its transaction overview. Reuters coverage of the Globus-NuVasive deal closing

How analysts frame the combined group

Sell-side analysts covering Globus Medical Inc and NuVasive have highlighted that the combined company now competes more directly with larger spine and orthopedics peers such as Medtronic and Stryker, with increased scale in the U.S. and international markets and a broader implant and enabling technology portfolio, according to recent research commentary. MarketScreener consensus overview for Globus Medical

Research notes around the time of the NuVasive deal close pointed out that the enlarged Globus Medical Inc group should benefit from a more diversified product mix across spine implants, biologics and surgical navigation systems, but that integration execution and realization of targeted synergies will be key determinants of future margin progression, as several analyst reports have emphasized. Wall Street Journal summary of GMED analyst ratings

The product behind the stock

Globus Medical Inc generates most of its revenue from spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform that supports minimally invasive spine procedures and is sold into hospitals and surgical centers as part of its musculoskeletal solutions portfolio.

Where the stock trades today

Globus Medical Inc Class A shares last traded at 64.00 USD on NASDAQ, based on recent quote data accessed on 2026-06-26, 16:30.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.